Autor: |
Legault EM; Faculty of Pharmacy, Université de Montréal, Montreal, Canada., Bouquety J; Faculty of Pharmacy, Université de Montréal, Montreal, Canada., Drouin-Ouellet J; Faculty of Pharmacy, Université de Montréal, Montreal, Canada. |
Jazyk: |
angličtina |
Zdroj: |
Cellular reprogramming [Cell Reprogram] 2022 Oct; Vol. 24 (5), pp. 228-251. Date of Electronic Publication: 2022 Jun 24. |
DOI: |
10.1089/cell.2021.0172 |
Abstrakt: |
Understanding the pathophysiology of CNS-associated neurological diseases has been hampered by the inaccessibility of patient brain tissue to perform live analyses at the molecular level. To this end, neural cells obtained by differentiation of patient-derived induced pluripotent stem cells (iPSCs) are considerably helpful, especially in the context of monogenic-based disorders. More recently, the use of direct reprogramming to convert somatic cells to neural cells has emerged as an alternative to iPSCs to generate neurons, astrocytes, and oligodendrocytes. This review focuses on the different studies that used direct neural reprogramming to study disease-associated phenotypes in the context of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. |
Databáze: |
MEDLINE |
Externí odkaz: |
|